FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000000012> ?p ?o ?g. }

• W3000000012 endingPage "542" @default.
• W3000000012 startingPage "523" @default.
• W3000000012 abstract "Background:Parkinson’s disease (PD) is a progressive neurodegenerative disease for which there is no cure. In a clinical trial, the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 has shown good protective effects in PD patients. The hormone glucose-dependent insulinotropic polypeptide ( GIP) has also shown protective effects in animal models of PD. Objective:We tested DA-CH5, a novel dual GLP-1/GIP receptor agonist. Methods:DA-CH5 activity was tested on cells expressing GLP-1, GLP-2, GIP or glucagon receptors. The ability to cross the blood-brain barrier (BBB) of DA-CH5, exendin-4, liraglutide or other dual receptor agonists was tested with fluorescein-labelled peptides. DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD. Results:Analysing the receptor activating properties showed a balanced activation of GLP-1 and GIP receptors while not activating GLP-2 or glucagon receptors. DA-CH5 crossed the BBB better than other single or other dual receptor agonists. In a dose-response comparison, DA-CH5 was more effective than the GLP-1 receptor agonist exendin-4. When comparing the neuroprotective effect of DA-CH5 with Liraglutide, a GLP-1 analogue, both DA-CH5 and Liraglutide improved MPTP-induced motor impairments. In addition, the drugs reversed the decrease of the number of neurons expressing tyrosine hydroxylase (TH) in the SN, alleviated chronic inflammation, reduced lipid peroxidation, inhibited the apoptosis pathway (TUNEL assay) and increased autophagy -related proteins expression in the substantia nigra (SN) and striatum. Importantly, we found DA-CH5 was superior to Liraglutide in reducing microglia and astrocyte activation, improving mitochondrial activity by reducing the Bax/Bcl-2 ratio and normalising autophagy as found in abnormal expression of LC3 and p62. Conclusion:The results demonstrate that the DA-CH5 is superior to liraglutide and could be a therapeutic treatment for PD." @default.
• W3000000012 created "2020-01-23" @default.
• W3000000012 creator A5004986940 @default.
• W3000000012 creator A5010661160 @default.
• W3000000012 creator A5035872776 @default.
• W3000000012 creator A5047385098 @default.
• W3000000012 creator A5067028141 @default.
• W3000000012 creator A5078233398 @default.
• W3000000012 creator A5082707086 @default.
• W3000000012 date "2020-04-03" @default.
• W3000000012 modified "2023-10-16" @default.
• W3000000012 title "The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease" @default.
• W3000000012 cites W1041790731 @default.
• W3000000012 cites W1680009796 @default.
• W3000000012 cites W1795219500 @default.
• W3000000012 cites W1886384046 @default.
• W3000000012 cites W1966591940 @default.
• W3000000012 cites W1967442749 @default.
• W3000000012 cites W1968995247 @default.
• W3000000012 cites W1975774284 @default.
• W3000000012 cites W1978143294 @default.
• W3000000012 cites W1986216002 @default.
• W3000000012 cites W1996170441 @default.
• W3000000012 cites W1999018495 @default.
• W3000000012 cites W2000631088 @default.
• W3000000012 cites W2007649442 @default.
• W3000000012 cites W2009700583 @default.
• W3000000012 cites W2013301138 @default.
• W3000000012 cites W2019530565 @default.
• W3000000012 cites W2024639041 @default.
• W3000000012 cites W2026462831 @default.
• W3000000012 cites W2057113150 @default.
• W3000000012 cites W2057274775 @default.
• W3000000012 cites W2058381475 @default.
• W3000000012 cites W2069642809 @default.
• W3000000012 cites W2075798709 @default.
• W3000000012 cites W2086172007 @default.
• W3000000012 cites W2088318694 @default.
• W3000000012 cites W2094023488 @default.
• W3000000012 cites W2102071852 @default.
• W3000000012 cites W2125461230 @default.
• W3000000012 cites W2126148709 @default.
• W3000000012 cites W2129917779 @default.
• W3000000012 cites W2134238969 @default.
• W3000000012 cites W2145399920 @default.
• W3000000012 cites W2149717292 @default.
• W3000000012 cites W2151317627 @default.
• W3000000012 cites W2164948885 @default.
• W3000000012 cites W2166688610 @default.
• W3000000012 cites W2178105210 @default.
• W3000000012 cites W2199406275 @default.
• W3000000012 cites W2211963426 @default.
• W3000000012 cites W2331605285 @default.
• W3000000012 cites W2336659823 @default.
• W3000000012 cites W2399787808 @default.
• W3000000012 cites W2401820359 @default.
• W3000000012 cites W2468864843 @default.
• W3000000012 cites W2469476726 @default.
• W3000000012 cites W2484914234 @default.
• W3000000012 cites W2514313369 @default.
• W3000000012 cites W2515408417 @default.
• W3000000012 cites W2528242093 @default.
• W3000000012 cites W2559570574 @default.
• W3000000012 cites W2588262749 @default.
• W3000000012 cites W2589420593 @default.
• W3000000012 cites W2599792256 @default.
• W3000000012 cites W2728605505 @default.
• W3000000012 cites W2759773112 @default.
• W3000000012 cites W2761876599 @default.
• W3000000012 cites W2770385888 @default.
• W3000000012 cites W2784233170 @default.
• W3000000012 cites W2785903681 @default.
• W3000000012 cites W2791252329 @default.
• W3000000012 cites W2824830902 @default.
• W3000000012 cites W2895666357 @default.
• W3000000012 cites W2908881986 @default.
• W3000000012 cites W4211044101 @default.
• W3000000012 cites W4254570323 @default.
• W3000000012 cites W62603772 @default.
• W3000000012 cites W863873638 @default.
• W3000000012 doi "https://doi.org/10.3233/jpd-191768" @default.
• W3000000012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31958096" @default.
• W3000000012 hasPublicationYear "2020" @default.
• W3000000012 type Work @default.
• W3000000012 sameAs 3000000012 @default.
• W3000000012 citedByCount "42" @default.
• W3000000012 countsByYear W30000000122020 @default.
• W3000000012 countsByYear W30000000122021 @default.
• W3000000012 countsByYear W30000000122022 @default.
• W3000000012 countsByYear W30000000122023 @default.
• W3000000012 crossrefType "journal-article" @default.
• W3000000012 hasAuthorship W3000000012A5004986940 @default.
• W3000000012 hasAuthorship W3000000012A5010661160 @default.
• W3000000012 hasAuthorship W3000000012A5035872776 @default.
• W3000000012 hasAuthorship W3000000012A5047385098 @default.
• W3000000012 hasAuthorship W3000000012A5067028141 @default.
• W3000000012 hasAuthorship W3000000012A5078233398 @default.
• W3000000012 hasAuthorship W3000000012A5082707086 @default.

• next